Plantina has been acquired by Nutramin
E. de Groot and G. Schuitemaker, private shareholders of Plantina, have sold the company to Nutramin.
Plantina is a developer and supplier of branded food supplements primarily for the Dutch market and, to a lesser extent, for the Belgian and German markets. The company's products are marketed under the strong and renowned Plantina brand and Performax in Germany. The Plantina brand is known for its superior quality and effectiveness due to its choice of raw materials and suppliers, and its relative high dosing.
Founded in 1982, Nutramin is a developer and supplier of food supplements with a focus on healthcare professionals, doctors and therapists. Additionally, the company provides informative services such as conferences in congresses, master classes and training sessions which highlight its academic and professional background.
Oaklins' team in the Netherlands advised the seller in this transaction.


Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more